vs
Side-by-side financial comparison of Lilly (Eli) (LLY) and Phillips 66 (PSX). Click either name above to swap in a different company.
Phillips 66 is the larger business by last-quarter revenue ($34.1B vs $19.3B, roughly 1.8× Lilly (Eli)). Lilly (Eli) runs the higher net margin — 34.4% vs 8.5%, a 25.9% gap on every dollar of revenue. On growth, Lilly (Eli) posted the faster year-over-year revenue change (42.6% vs 1.3%). Over the past eight quarters, Lilly (Eli)'s revenue compounded faster (48.3% CAGR vs -2.4%).
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The Phillips 66 Company is an American multinational energy company headquartered in Westchase, Houston, Texas. Its name, dating back to 1927 as a trademark of the Phillips Petroleum Company, assisted in establishing the newly reconfigured Phillips 66. The company today was formed ten years after Phillips merged with Conoco to form ConocoPhillips.
LLY vs PSX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.3B | $34.1B |
| Net Profit | $6.6B | $2.9B |
| Gross Margin | 82.5% | 14.6% |
| Operating Margin | 42.8% | — |
| Net Margin | 34.4% | 8.5% |
| Revenue YoY | 42.6% | 1.3% |
| Net Profit YoY | 50.5% | 36225.0% |
| EPS (diluted) | $7.39 | $7.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $19.3B | $34.1B | ||
| Q3 25 | $17.6B | $34.5B | ||
| Q2 25 | $15.6B | $33.3B | ||
| Q1 25 | $12.7B | $30.4B | ||
| Q4 24 | $13.5B | $33.7B | ||
| Q3 24 | $11.4B | $35.5B | ||
| Q2 24 | $11.3B | $38.1B | ||
| Q1 24 | $8.8B | $35.8B |
| Q4 25 | $6.6B | $2.9B | ||
| Q3 25 | $5.6B | $133.0M | ||
| Q2 25 | $5.7B | $877.0M | ||
| Q1 25 | $2.8B | $487.0M | ||
| Q4 24 | $4.4B | $8.0M | ||
| Q3 24 | $970.3M | $346.0M | ||
| Q2 24 | $3.0B | $1.0B | ||
| Q1 24 | $2.2B | $748.0M |
| Q4 25 | 82.5% | 14.6% | ||
| Q3 25 | 82.9% | 12.4% | ||
| Q2 25 | 84.3% | 12.7% | ||
| Q1 25 | 82.5% | 9.1% | ||
| Q4 24 | 82.2% | 8.7% | ||
| Q3 24 | 81.0% | 9.4% | ||
| Q2 24 | 80.8% | 9.2% | ||
| Q1 24 | 80.9% | 9.6% |
| Q4 25 | 42.8% | — | ||
| Q3 25 | 41.1% | — | ||
| Q2 25 | 43.6% | — | ||
| Q1 25 | 27.2% | — | ||
| Q4 24 | 37.2% | — | ||
| Q3 24 | 13.9% | — | ||
| Q2 24 | 31.1% | — | ||
| Q1 24 | 28.9% | — |
| Q4 25 | 34.4% | 8.5% | ||
| Q3 25 | 31.7% | 0.4% | ||
| Q2 25 | 36.4% | 2.6% | ||
| Q1 25 | 21.7% | 1.6% | ||
| Q4 24 | 32.6% | 0.0% | ||
| Q3 24 | 8.5% | 1.0% | ||
| Q2 24 | 26.3% | 2.7% | ||
| Q1 24 | 25.6% | 2.1% |
| Q4 25 | $7.39 | $7.14 | ||
| Q3 25 | $6.21 | $0.32 | ||
| Q2 25 | $6.29 | $2.15 | ||
| Q1 25 | $3.06 | $1.18 | ||
| Q4 24 | $4.88 | $0.06 | ||
| Q3 24 | $1.07 | $0.82 | ||
| Q2 24 | $3.28 | $2.38 | ||
| Q1 24 | $2.48 | $1.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.3B | $1.1B |
| Total DebtLower is stronger | — | $18.7B |
| Stockholders' EquityBook value | $26.5B | $29.1B |
| Total Assets | $112.5B | $73.7B |
| Debt / EquityLower = less leverage | — | 0.64× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.3B | $1.1B | ||
| Q3 25 | $9.9B | $1.8B | ||
| Q2 25 | $3.5B | $1.1B | ||
| Q1 25 | $3.2B | $1.5B | ||
| Q4 24 | $3.4B | $1.7B | ||
| Q3 24 | $3.5B | $1.6B | ||
| Q2 24 | $3.4B | $2.4B | ||
| Q1 24 | $2.6B | $1.6B |
| Q4 25 | — | $18.7B | ||
| Q3 25 | — | $19.2B | ||
| Q2 25 | — | $17.2B | ||
| Q1 25 | — | $17.7B | ||
| Q4 24 | $29.5B | $18.2B | ||
| Q3 24 | — | $18.5B | ||
| Q2 24 | — | $17.2B | ||
| Q1 24 | — | $17.8B |
| Q4 25 | $26.5B | $29.1B | ||
| Q3 25 | $23.8B | $26.9B | ||
| Q2 25 | $18.3B | $27.5B | ||
| Q1 25 | $15.8B | $27.3B | ||
| Q4 24 | $14.2B | $27.4B | ||
| Q3 24 | $14.2B | $28.7B | ||
| Q2 24 | $13.6B | $29.5B | ||
| Q1 24 | $12.8B | $29.7B |
| Q4 25 | $112.5B | $73.7B | ||
| Q3 25 | $114.9B | $76.1B | ||
| Q2 25 | $100.9B | $75.9B | ||
| Q1 25 | $89.4B | $71.8B | ||
| Q4 24 | $78.7B | $72.6B | ||
| Q3 24 | $75.6B | $75.1B | ||
| Q2 24 | $71.9B | $75.9B | ||
| Q1 24 | $63.9B | $76.4B |
| Q4 25 | — | 0.64× | ||
| Q3 25 | — | 0.71× | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | 0.65× | ||
| Q4 24 | 2.08× | 0.67× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.58× | ||
| Q1 24 | — | 0.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.2B | $2.8B |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.49× | 0.95× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.2B | $2.8B | ||
| Q3 25 | $8.8B | $1.2B | ||
| Q2 25 | $3.1B | $845.0M | ||
| Q1 25 | $1.7B | $187.0M | ||
| Q4 24 | $2.5B | $1.2B | ||
| Q3 24 | $3.7B | $1.1B | ||
| Q2 24 | $1.5B | $2.1B | ||
| Q1 24 | $1.2B | $-236.0M |
| Q4 25 | 0.49× | 0.95× | ||
| Q3 25 | 1.58× | 8.86× | ||
| Q2 25 | 0.55× | 0.96× | ||
| Q1 25 | 0.60× | 0.38× | ||
| Q4 24 | 0.56× | 149.75× | ||
| Q3 24 | 3.83× | 3.27× | ||
| Q2 24 | 0.49× | 2.07× | ||
| Q1 24 | 0.52× | -0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LLY
| Other | $5.4B | 28% |
| Zepbound | $4.2B | 22% |
| Mounjaro | $4.1B | 21% |
| Verzenio | $997.1M | 5% |
| Collaborationand Other Revenue | $991.7M | 5% |
| Taltz | $724.3M | 4% |
| Trulicity | $692.8M | 4% |
| Other Cardiometabolic Health | $524.5M | 3% |
| Other Oncology | $514.8M | 3% |
| Jardiance | $465.8M | 2% |
| Neuroscience | $320.2M | 2% |
| Other Immunology | $187.3M | 1% |
| Other Product Total | $77.0M | 0% |
PSX
| Marketing Speciality Segment | $21.7B | 64% |
| Crude Oil | $3.7B | 11% |
| GB | $3.5B | 10% |
| Other Geographical Areas | $2.4B | 7% |
| DE | $1.1B | 3% |
| Renewable Fuels | $876.0M | 3% |
| Other Product Line | $634.0M | 2% |
